Genelux (GNLX) Non-Current Assets (2022 - 2026)
Genelux (GNLX) recorded quarterly Non-Current Assets of $5.6 million in Q1 2026, up 44.16% quarter-over-quarter from $3.9 million in Q4 2025.
Genelux (GNLX) Non-Current Assets (2022 - 2026) Analysis & Trends
Genelux's Non-Current Assets history runs 5 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Non-Current Assets changed N/A year-over-year to $5.6 million; the TTM figure through Sep 2025 stood at $3.4 million (down 20.17% YoY), while the FY2025 annual figure was $3.9 million, up 23.01% from the prior year.
- Non-Current Assets was $5.6 million for Q1 2026 at Genelux, up from $3.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $10.3 million in Q2 2024 to a low of $2.9 million in Q3 2023.
- Historically, Non-Current Assets has averaged $4.3 million across 5 years, with a median of $3.6 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 48.74% in 2024, then slumped 70.78% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $3.6 million in 2022, then advanced by 1.4% to $3.7 million in 2023, then decreased by 14.15% to $3.2 million in 2024, then increased by 23.01% to $3.9 million in 2025, then surged by 44.16% to $5.6 million in 2026.
- The last three Non-Current Assets figures came in at $5.6 million (Q1 2026), $3.9 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.62 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Sep 30, 2025 | 3.44 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Dec 31, 2024 | 3.17 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 10.31 Mn |
| Mar 31, 2024 | 3.47 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 2.89 Mn |
| Dec 31, 2022 | 3.64 Mn |